JP2016510045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510045A5 JP2016510045A5 JP2015560572A JP2015560572A JP2016510045A5 JP 2016510045 A5 JP2016510045 A5 JP 2016510045A5 JP 2015560572 A JP2015560572 A JP 2015560572A JP 2015560572 A JP2015560572 A JP 2015560572A JP 2016510045 A5 JP2016510045 A5 JP 2016510045A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- disorders
- disease
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010028537 Myelofibrosis Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 1
- 208000009174 Transverse Myelitis Diseases 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003376 axonal Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003210 demyelinating Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Description
1.NSAID(非ステロイド系抗炎症薬)および鎮痛剤
2.グルココルチコイド(低経口用量)
3.慣用の疾患修飾性抗リウマチ薬(DMARD)
− メトトレキサート
− レフルノミド
− スルファサラジン
− ヒドロキシクロロキン
− アザチオプリン
− シクロスポリン
− ミノサイクリン
− 金
2.グルココルチコイド(低経口用量)
3.慣用の疾患修飾性抗リウマチ薬(DMARD)
− メトトレキサート
− レフルノミド
− スルファサラジン
− ヒドロキシクロロキン
− アザチオプリン
− シクロスポリン
− ミノサイクリン
− 金
本発明の請求項1に記載の化合物ならびに/またはそれらの生理学的に許容し得る塩および溶媒和物の、神経障害、特に神経変性疾患、例えば軸索変性によって、またはタンパク質プラーク堆積によって生じた疾患の処置または防止のための医薬の製造のための使用がまた、含有される。神経変性疾患は、例えば脱髄性コア障害、例えば多発性硬化症、急性横断性脊髄炎、筋萎縮性側索硬化症、クロイツフェルト・ヤコブ病またはアルツハイマー病を含む。
別の態様において、線維症の疾患および障害の処置または防止のための方法を、本明細書中に提供する。特別の態様において、特発性肺線維症、骨髄線維症、肝臓の線維症、ステアトフィブロシス(steatofibrosis)および脂肪性肝炎の処置または防止のための方法を、本明細書中に提供する。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13001111 | 2013-03-05 | ||
EP13001111.7 | 2013-03-05 | ||
PCT/EP2014/000371 WO2014135245A1 (en) | 2013-03-05 | 2014-02-11 | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016510045A JP2016510045A (ja) | 2016-04-04 |
JP2016510045A5 true JP2016510045A5 (ja) | 2017-03-16 |
JP6409007B2 JP6409007B2 (ja) | 2018-10-17 |
Family
ID=47843002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015560572A Expired - Fee Related JP6409007B2 (ja) | 2013-03-05 | 2014-02-11 | 抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9617266B2 (ja) |
EP (1) | EP2964648B1 (ja) |
JP (1) | JP6409007B2 (ja) |
CN (1) | CN105026397B (ja) |
AR (1) | AR094981A1 (ja) |
AU (1) | AU2014224976B2 (ja) |
CA (1) | CA2903901A1 (ja) |
ES (1) | ES2614872T3 (ja) |
IL (1) | IL240876B (ja) |
WO (1) | WO2014135245A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX369863B (es) | 2013-08-23 | 2019-11-25 | Neupharma Inc | Ciertas entidades quimicas, composiciones y metodos. |
WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
IL283834B (en) | 2014-09-28 | 2022-07-01 | Univ California | Modulation of stimulatory and non-stimulatory myeloid cells |
WO2016133935A1 (en) | 2015-02-17 | 2016-08-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN104788441A (zh) * | 2015-04-02 | 2015-07-22 | 湖南华腾制药有限公司 | 一种多取代苯并恶唑衍生物的制备方法 |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
AR108665A1 (es) * | 2016-06-02 | 2018-09-12 | Celgene Corp | Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania |
ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
UA126231C2 (uk) | 2016-06-16 | 2022-09-07 | Деналі Терапьютікс Інк. | Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань |
CN109790122B (zh) | 2016-08-10 | 2022-06-24 | 武田药品工业株式会社 | 杂环化合物 |
EP3497087B1 (en) | 2016-08-15 | 2021-11-10 | Neupharma, Inc. | Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer |
KR102579849B1 (ko) | 2016-12-22 | 2023-09-18 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성을 억제시키기 위한 조성물 및 방법 |
KR102383561B1 (ko) * | 2017-09-07 | 2022-04-06 | 한국화학연구원 | 테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
CN111936136A (zh) | 2017-11-14 | 2020-11-13 | 儿童医学中心公司 | 新咪唑并嘧啶化合物及其用途 |
KR20200088398A (ko) | 2017-11-14 | 2020-07-22 | 칠드런'즈 메디컬 센터 코포레이션 | 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도 |
AU2018383709A1 (en) | 2017-12-12 | 2020-07-16 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
WO2019136466A1 (en) * | 2018-01-08 | 2019-07-11 | Yale University | Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations |
TWI816742B (zh) * | 2018-01-29 | 2023-10-01 | 美商維泰克斯製藥公司 | Gcn2抑制劑及其用途 |
JP2021527051A (ja) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 |
CN111166750B (zh) * | 2018-11-09 | 2022-12-27 | 四川大学 | 一种4-氟-2-甲基吲哚类化合物的抗菌新用途 |
GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
EP1301497A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
CA2531333A1 (en) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
CN101022799A (zh) | 2004-07-19 | 2007-08-22 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
CN101048410B (zh) | 2004-10-29 | 2010-06-23 | 泰博特克药品有限公司 | 抑制hiv的双环嘧啶衍生物 |
ZA200706662B (en) * | 2005-01-13 | 2009-04-29 | Signal Pharmaceiticals Llc | Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith |
US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
CA2592457A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
WO2011106168A1 (en) * | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
US9023851B2 (en) * | 2010-08-27 | 2015-05-05 | Merck Patent Gmbh | Triazolopyrazine derivatives |
-
2014
- 2014-02-11 AU AU2014224976A patent/AU2014224976B2/en not_active Ceased
- 2014-02-11 JP JP2015560572A patent/JP6409007B2/ja not_active Expired - Fee Related
- 2014-02-11 CN CN201480012134.3A patent/CN105026397B/zh not_active Expired - Fee Related
- 2014-02-11 CA CA2903901A patent/CA2903901A1/en not_active Abandoned
- 2014-02-11 ES ES14705029.8T patent/ES2614872T3/es active Active
- 2014-02-11 US US14/772,430 patent/US9617266B2/en active Active
- 2014-02-11 EP EP14705029.8A patent/EP2964648B1/en not_active Not-in-force
- 2014-02-11 WO PCT/EP2014/000371 patent/WO2014135245A1/en active Application Filing
- 2014-03-05 AR ARP140100696A patent/AR094981A1/es unknown
-
2015
- 2015-08-27 IL IL240876A patent/IL240876B/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016510045A5 (ja) | ||
CL2019001978A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo. | |
JP2015120736A5 (ja) | ||
JP2016535786A5 (ja) | ||
EA201071244A1 (ru) | Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза | |
JP2017222722A5 (ja) | ||
WO2012149389A3 (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders | |
WO2016087944A3 (en) | Method for treating alzheimer's disease | |
EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью | |
RU2017105353A (ru) | Соединения | |
JP2015500223A5 (ja) | ||
UA113750C2 (xx) | Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону | |
WO2017062500A3 (en) | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies | |
MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
JP2015520221A5 (ja) | ||
BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
WO2015025226A3 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
JP2017501140A5 (ja) | ||
EP3088898A4 (en) | Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents | |
MX2018008439A (es) | Orvepitant para el tratamiento de la tos cronica. | |
EP3796980A4 (en) | NEW THERAPY FOR ALZHEIMER'S DISEASE | |
ZA202205344B (en) | Gene therapy for alzheimer's disease | |
CL2021000160A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
WO2006016219A3 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |